New radioactive drug shows promise for Hard-to-Treat cancers
NCT ID NCT07439120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new radioactive drug (BRP-020063) in 10 people with advanced solid tumors that have spread. The drug is used first for imaging to find tumors, then a low dose is given to see if it's safe and how it travels in the body. The goal is to gather information for future, higher-dose treatment studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- A simple urine test could revolutionize bladder cancer detection
- Could a drug combo spare bladder cancer patients from surgery?
- New drug duo takes on advanced bladder cancer in early trial
- New drug targets hard-to-treat cancers in early trial
- New hope for advanced HER2 cancers? drug trial launches